Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 3 December 2025 - 7 December 2025

CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics AG (NASDAQ: CRSP) is finishing 2025 in classic high‑beta biotech fashion: big science, big headlines, and big disagreement about where the stock goes next. As of the last U.S. trading session on Friday, 5 December 2025, CRSP changed hands at about $56.88 per share, implying a market value just under $5.9 billion. The stock sits well above its 52‑week low near $30 but below its high around $78, underlining just how wild the ride has been for gene‑editing investors.MarketBeat Below is a rundown of the latest news, institutional moves, analyst forecasts and technical signals as of 7 December
7 December 2025
··
INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

Published: December 7, 2025 Inovio Pharmaceuticals (NASDAQ: INO) has quietly turned 2025 into a make‑or‑break year. The small‑cap biotech has completed a Biologics License Application (BLA) for its lead DNA immunotherapy INO‑3107, raised fresh capital through two stock offerings, and attracted a flurry of new analyst ratings and algorithmic “Strong Buy” labels — all while still burning cash and generating minimal revenue. GuruFocus+3Yahoo Finance+3Stock Titan+3 As of the last trading session on Friday, December 5, 2025, INO stock closed at $2.07, up about 2.5% on the day and roughly 19–20% over the past 10 trading sessions, with around 1 million
7 December 2025
·····
Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna Inc. (NASDAQ: MRNA) is back in the spotlight. After months of pressure from collapsing COVID‑19 vaccine demand and rising regulatory scrutiny, the stock has staged a sharp rebound in early December 2025 — powered by a major long‑term safety study from France and a new $1.5 billion credit facility. Here’s a deep dive into the latest news, forecasts, and analyses around Moderna stock from December 6, 2025 onward, and what they collectively suggest for the company’s risk‑reward profile. Moderna stock today: sharp bounce, still bruised As of the close on December 5, 2025, Moderna shares finished at $27.70, up
6 December 2025
····
Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges

Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges

As of the close on Friday, December 5, 2025, Ocular Therapeutix, Inc. (NASDAQ: OCUL) finished regular trading at $12.58 per share, up about 1.2% on the day, with after‑hours quotes on some platforms briefly touching the $14 area. StockAnalysis+1 The move caps a strong week: on Thursday the stock jumped roughly 12.3% to around $12.87, well above its recent averages, as traders responded to a new regulatory strategy for its lead retina drug AXPAXLI and fresh analyst commentary. MarketBeat+1 At the same time, OCUL remains firmly in “story stock” biotech territory: still loss‑making, heavily dependent on its late‑stage pipeline, but
6 December 2025
·····
Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna, Inc. (NASDAQ: MRNA) closed today as one of the more talked‑about healthcare names on Wall Street, with the stock rebounding sharply after a bruising year of falling COVID-19 vaccine sales, pipeline setbacks, and rising regulatory risk. Today’s move comes as investors digest a huge, real‑world French study supporting the long‑term safety and effectiveness of mRNA COVID vaccines, fresh details of a $1.5 billion loan deal, and updated guidance pointing to a slow path back toward growth and eventual profitability. The Chronicle-Journal+1 Below is a deep dive into where Moderna stock stands right now, what’s driving today’s rally, and how
5 December 2025
····
Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Published: December 5, 2025 Key Takeaways This article summarizes the latest news, forecasts, and analyses on Aditxt, Inc. (NASDAQ: ADTX) as of December 5, 2025, based on regulatory filings, company press releases and market data. It is informational only and not investment advice. ADTX Stock Price Today: Tiny Float, Huge Swings As of mid‑day U.S. trading on December 5, 2025, Aditxt (ADTX) is changing hands at roughly $3.00–3.05 per share, up low‑single digits versus the prior close of $2.91. Daily trading volume is in the 3.2–3.3 million share range, unusually high relative to its tiny float.StockAnalysis Key intraday and trailing
5 December 2025
·····
SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc Ltd. (NASDAQ: SPRC) is back on traders’ radar after a frenetic week of news that spans quantum bio‑data analytics, medical endoscopy devices and ongoing restructuring of its biotech portfolio. As of Friday, December 5, 2025, SciSparc shares are trading around $1.79–$1.80, after an early pre‑market jump of about 19% to $2.10, on volume that has already surged well above normal levels. StockAnalysis+1 Despite today’s bounce, the stock remains down roughly 60–75% over the past year and more than 95% below its 52‑week high of $37.59, leaving the company with a micro‑cap market value of roughly $5.6–$5.9 million. INDmoney+2Stock Titan+2
5 December 2025
···
Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical, Inc. (NYSE American: PMI) just staged one of the most dramatic moves on Wall Street, with its stock surging more than 80% on December 4, 2025, after the company released new data on its next‑generation artificial heart. Investors are now asking a simple question: is this the start of a longer rerating, or just another spike in a highly volatile microcap? Picard Medical Stock at a Glance (as of December 4, 2025) On December 4, 2025, Picard Medical shares closed at $3.69, up $1.67 (+82.67%) from the prior close of $2.02, making PMI one of the top gainers
5 December 2025
·····
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon Ltd. (NASDAQ: PLRZ) has gone from obscure micro‑cap to headline‑grabbing biotech in just two trading days. On December 4, 2025, the stock was changing hands in the mid‑teens, more than doubling from the prior close of $7.09, with intraday swings between roughly $12.5 and $18.2 and volume near 26 million shares – over 20× its recent average. MarketBeat+1 Behind this violent move are two concrete catalysts: At the same time, quantitative services and technical models are sending mixed—and often cautious—signals, with several “Strong Sell” ratings even as momentum screens flash “Buy” or “Strong Buy.” TipRanks+4Danelfin AI+4TradingView+4 This article walks
4 December 2025
·····
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

Updated: December 4, 2025 Key takeaways CRISPR Therapeutics stock today: price, volatility and positioning As of pre‑market trading on December 4, 2025, CRISPR Therapeutics AG (NASDAQ: CRSP) is changing hands at roughly $56, just above Wednesday’s close of $55.99, after jumping 8.5% in the last regular session. stockinvest.us+1 Over the past 12 months, CRSP has traded between about $30.04 and $78.48, leaving today’s price squarely in the middle of its 52‑week range. stockinvest.us A few quick stats: Technically, services like StockInvest.us classify CRSP as a “hold/accumulate” with a wide expected three‑month range (~$43–$64), while Intellectia’s model calls it a “Strong
4 December 2025
·····
Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Updated: December 4, 2025 – mid‑day U.S. trading Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just pulled off the kind of move small‑cap biotech traders dream about and risk managers lose sleep over. After releasing decisive Phase 3 data for its Duchenne muscular dystrophy (DMD) cell therapy Deramiocel, the stock has exploded several hundred percent in barely two trading sessions and is now hovering around $29.96 per share. The HOPE‑3 trial didn’t just “meet endpoints” in a boring, incremental way. It showed a 54% slowing of upper‑limb functional decline and 91% preservation of heart function versus placebo – in a disease
4 December 2025
·····
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight. On December 3, 2025, the pharma giant’s share price jumped more than 6% intraday to around $51.32, extending a multi‑day rebound driven by a mix of clinical trial news, AI‑driven R&D milestones, and fresh analyst calls. StockAnalysis At the same time, investors are weighing sizable legal risks and an approaching patent cliff — making BMY one of the more eventful large‑cap healthcare stocks to watch into 2026. Below is a comprehensive, SEO‑friendly rundown of today’s Bristol-Myers Squibb stock news, forecasts, and analysis as of December 3, 2025. BMY Stock Price
3 December 2025
····
1 … 13 14 15 16 17 … 25

Stock Market Today

Halma share price: Friday’s lift sets up what investors watch next week

Halma share price: Friday’s lift sets up what investors watch next week

7 February 2026
Halma shares closed up 0.7% at 3,548 pence on Friday, valuing the group at about £13.4 billion. The Bank of England held rates at 3.75% in a split vote, keeping rate-cut speculation in focus. Halma’s next trading update is set for March 12. The FTSE 100 ended the week up 0.6%, lifted by bank stocks.
Diageo share price slips into the weekend as investors eye Feb. 25 results

Diageo share price slips into the weekend as investors eye Feb. 25 results

7 February 2026
Diageo shares closed down 1.48% at 1,760 pence on Friday, trailing a 0.59% gain in the FTSE 100. An updated analyst consensus points to a 2.0% fall in first-half organic net sales ahead of interim results due Feb. 25. Trading volume was light, and the stock remains over 22% below its 52-week high.
National Grid share price: what to know before London reopens after BoE signal

National Grid share price: what to know before London reopens after BoE signal

7 February 2026
National Grid shares closed at 1,285 pence in London on Friday, up 0.23%. The Bank of England held rates at 3.75% after a close vote, signaling possible cuts if inflation falls. National Grid announced a wireless power transmission study with Space Solar and marked five years of IFA2 interconnector operations. Its U.S. ADR ended at $88.06, up $1.17.
BAE Systems share price rises into weekend — what to watch before Monday’s London open

BAE Systems share price rises into weekend — what to watch before Monday’s London open

7 February 2026
BAE Systems shares closed up 1.2% at 1,879 pence on Friday, tracking gains in European defence stocks. The company’s market value stands near £54.8 billion. Investors await BAE’s full-year results on Feb. 18 for updates on cash returns and orders. GXO Logistics renewed and expanded its contract to support BAE’s Type 26 frigate program in Scotland.
Go toTop